相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Identification and Characterization of Tumor-Initiating Cells in Multiple Myeloma
Minjie Gao et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
An update on extracellular vesicles in multiple myeloma: a focus on their role in cell-to-cell cross-talk and as potential liquid biopsy biomarkers
Luciana De Luca et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2019)
Recycling therapies for myeloma: The need for prospective trials
Shaji K. Kumar
CANCER (2019)
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline
Joseph Mikhael et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Novel targets for the treatment of relapsing multiple myeloma
Nicola Giuliani et al.
EXPERT REVIEW OF HEMATOLOGY (2019)
Multiple myeloma: Every year a new standard?
S. Vincent Rajkumar
HEMATOLOGICAL ONCOLOGY (2019)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al.
LANCET (2019)
Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
Benjamin G. Barwick et al.
FRONTIERS IN IMMUNOLOGY (2019)
The multi-factorial nature of clinical multidrug resistance in cancer
Yehuda G. Assaraf et al.
DRUG RESISTANCE UPDATES (2019)
Responses to selinexor in multiple myeloma
Diana Romero
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Ajai Chari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Genomic landscape and chronological reconstruction of driver events in multiple myeloma
Francesco Maura et al.
NATURE COMMUNICATIONS (2019)
Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma
Carolina Marini et al.
ANNALS OF HEMATOLOGY (2019)
Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing
Shaji K. Kumar et al.
BLOOD (2019)
Exosome-Transmitted PSMA3 and PSMA3-AS1 Promote Proteasome Inhibitor Resistance in Multiple Myeloma
Hongxia Xu et al.
CLINICAL CANCER RESEARCH (2019)
Extracellular vesicles as a novel source of biomarkers in liquid biopsies for monitoring cancer progression and drug resistance
M. Helena Vasconcelos et al.
DRUG RESISTANCE UPDATES (2019)
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
A. Besse et al.
LEUKEMIA (2018)
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
C. S. Chim et al.
LEUKEMIA (2018)
Epigenetics in multiple myeloma: From mechanisms to therapy
Mohammad Alzrigat et al.
SEMINARS IN CANCER BIOLOGY (2018)
An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma
Vincent L. Hansen et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design
Paul G. Richardson et al.
FUTURE ONCOLOGY (2018)
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups
Niccolo Bolli et al.
LEUKEMIA (2018)
The multiple myelomas - current concepts in cytogenetic classification and therapy
Shaji K. Kumar et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
Robert A. Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Panobinostat andMultipleMyeloma in 2018
Andrew J. Yee et al.
ONCOLOGIST (2018)
Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Drug resistance in multiple myeloma
Pawel Robak et al.
CANCER TREATMENT REVIEWS (2018)
Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM).
Robert Z. Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma
Praful Ravi et al.
BLOOD CANCER JOURNAL (2018)
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia
Christine Chen et al.
BLOOD (2018)
Drug targets and resistance mechanisms in multiple myeloma
Janine Nass et al.
CANCER DRUG RESISTANCE (2018)
Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma
J. P. Laubach et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Which therapies will move to the front line for multiple myeloma?
Maria J. Cejalvo et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Multiple myeloma
Shaji K. Kumar et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Ajai Chari et al.
BLOOD (2017)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. Moreau et al.
ANNALS OF ONCOLOGY (2017)
Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States
Luciano J. Costa et al.
BLOOD ADVANCES (2017)
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
Paul G. Richardson et al.
BLOOD (2016)
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma
Niels W. C. J. van de Donk et al.
BLOOD (2016)
Global hypomethylation in myeloma is associated with poor prognosis
Jonathan I. Sive et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Molecular mechanisms in multiple myeloma drug resistance
Nicholas Nikesitch et al.
JOURNAL OF CLINICAL PATHOLOGY (2016)
Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives
S. Lonial et al.
LEUKEMIA (2016)
SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
H. Jiang et al.
LEUKEMIA (2016)
Multidrug resistant tumour cells shed more microvesicle-like EVs and less exosomes than their drug-sensitive counterpart cells
Vanessa Lopes-Rodrigues et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2016)
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
Inger S. Nijhof et al.
BLOOD (2016)
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
K. Martin Kortum et al.
BLOOD (2016)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo
Vidal Jarauta et al.
CANCER LETTERS (2016)
Understanding Cancer Drug Resistance by Developing and Studying Resistant Cell Line Models
Cristina P. R. Xavier et al.
CURRENT CANCER DRUG TARGETS (2016)
Treatment of relapsed and refractory multiple myeloma
Pieter Sonneveld et al.
HAEMATOLOGICA (2016)
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells
Katarzyna Baranowska et al.
ONCOTARGET (2016)
Treatment of relapsed and refractory multiple myeloma
Pieter Sonneveld et al.
HAEMATOLOGICA (2016)
Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds
Kathryn Lagrue et al.
BLOOD (2015)
Pathogenesis beyond the cancer clone(s) in multiple myeloma
Giada Bianchi et al.
BLOOD (2015)
Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma
Polly J. Talley et al.
BRITISH MEDICAL BULLETIN (2015)
Panobinostat for the Treatment of Multiple Myeloma
Jacob P. Laubach et al.
CLINICAL CANCER RESEARCH (2015)
Plasma cell leukemia: from biology to treatment
Tomas Jelinek et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
Brian A. Walker et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
I. S. Nijhof et al.
LEUKEMIA (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
A. Keith Stewart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat
Salma Afifi et al.
PHARMACOTHERAPY (2015)
Intercellular Transfer of Cancer Drug Resistance Traits by Extracellular Vesicles
Diana Sousa et al.
TRENDS IN MOLECULAR MEDICINE (2015)
Interpretation of cytogenetic results in multiple myeloma for clinical practice
A. M. Rajan et al.
BLOOD CANCER JOURNAL (2015)
Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
Reinaldo Franqui-Machin et al.
ONCOTARGET (2015)
Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
Wen-Chi Yang et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study
Paul G. Richardson et al.
LANCET HAEMATOLOGY (2015)
Identify multiple myeloma stem cells: Utopia?
Ilaria Saltarella et al.
WORLD JOURNAL OF STEM CELLS (2015)
Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma
Y. Yang et al.
LEUKEMIA (2015)
The role of P-glycoprotein in drug resistance in multiple myeloma
Joseph Abraham et al.
LEUKEMIA & LYMPHOMA (2015)
Current treatment landscape for relapsed and/or refractory multiple myeloma
Meletios A. Dimopoulos et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma
Adil Doganay Duru et al.
PLOS ONE (2015)
Combined autophagy and proteasome inhibition A phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma
Dan T. Vogl et al.
AUTOPHAGY (2014)
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Paul G. Richardson et al.
BLOOD (2014)
Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells
Jinheng Wang et al.
BLOOD (2014)
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
Andrew Spencer et al.
BLOOD (2014)
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
Yuan Xiao Zhu et al.
BLOOD (2014)
The Effects of Bortezomib on Bone Disease in Patients With Multiple Myeloma
Mohamad Mohty et al.
CANCER (2014)
No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers
Nianhang Chen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target
Arianna Ferrucci et al.
CLINICAL CANCER RESEARCH (2014)
SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
Jutta Deckert et al.
CLINICAL CANCER RESEARCH (2014)
Novel Drug Combinations for the Management of Relapsed/Refractory Multiple Myeloma
Saad Z. Usmani et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)
Patterns of Relapse or Progression After Bortezomib-Based Salvage Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Jae-Sook Ahn et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)
Cyclin D1 Amplification in Multiple Myeloma Is Associated With Multidrug Resistance Expression
Eman M. Sewify et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)
The potential of miRNAs as biomarkers for multiple myeloma
Alberto Rocci et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2014)
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib
Manuela Gambella et al.
HAEMATOLOGICA (2014)
The impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy
Naohiro Sekiguchi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2014)
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma
Lenka Kubiczkova et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2014)
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
Shaji K. Kumar et al.
LANCET ONCOLOGY (2014)
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesus F. San-Miguel et al.
LANCET ONCOLOGY (2014)
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
S. K. Kumar et al.
LEUKEMIA (2014)
IMWG consensus on risk stratification in multiple myeloma
W. J. Chng et al.
LEUKEMIA (2014)
Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the National Health and Nutritional Examination Survey
O Landgren et al.
LEUKEMIA (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Niccolo Bolli et al.
NATURE COMMUNICATIONS (2014)
Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
D. S. Siegel et al.
BLOOD CANCER JOURNAL (2014)
Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients
B. A. Walker et al.
BLOOD CANCER JOURNAL (2014)
MicroRNA: Important Player in the Pathobiology of Multiple Myeloma
Chonglei Bi et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1
Teresa S. Hawley et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma
P. Leif Bergsagel et al.
BLOOD (2013)
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias
Robert O'Connor et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
Shauna M. Collins et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth
Emanuela Leone et al.
CLINICAL CANCER RESEARCH (2013)
Aberrant microRNA expression in multiple myeloma
Konstantinos Dimopoulos et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2013)
The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma
Manik Chatterjee et al.
HAEMATOLOGICA (2013)
Extracellular vesicles: Exosomes, microvesicles, and friends
Graca Raposo et al.
JOURNAL OF CELL BIOLOGY (2013)
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression
Aldo M. Roccaro et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Fact or fiction - identifying the elusive multiple myeloma stem cell
Joshua Kellner et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Endoplasmic Reticulum Stress and the Unfolded Protein Response: Targeting the Achilles Heel of Multiple Myeloma
Lisa Vincenz et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
Meletios Dimopoulos et al.
LANCET ONCOLOGY (2013)
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesus San Miguel et al.
LANCET ONCOLOGY (2013)
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
Yuan Xiao Zhu et al.
LEUKEMIA & LYMPHOMA (2013)
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms
Jahangir Abdi et al.
ONCOTARGET (2013)
How to select among available options for the treatment of multiple myeloma
J. L. Harousseau
ANNALS OF ONCOLOGY (2012)
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
Jeffrey A. Zonder et al.
BLOOD (2012)
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Ravi Vij et al.
BLOOD (2012)
Aphase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
David S. Siegel et al.
BLOOD (2012)
Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells
Ze Tian et al.
BLOOD (2012)
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Andrzej J. Jakubowiak et al.
BLOOD (2012)
Interleukin-6 signaling pathway in targeted therapy for cancer
Yuqi Guo et al.
CANCER TREATMENT REVIEWS (2012)
A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells
Li Lin et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
S. K. Kumar et al.
LEUKEMIA (2012)
CD19-CD45low/-CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells
D. Kim et al.
LEUKEMIA (2012)
Arsenic Trioxide Exerts Antimyeloma Effects by Inhibiting Activity in the Cytoplasmic Substrates of Histone Deacetylase 6
Xiaoyan Qu et al.
PLOS ONE (2012)
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1
N. Amodio et al.
CELL DEATH & DISEASE (2012)
Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib
T. Ishii et al.
BLOOD CANCER JOURNAL (2012)
The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies
A. Kalff et al.
BLOOD CANCER JOURNAL (2012)
The genetic architecture of multiple myeloma
Gareth J. Morgan et al.
NATURE REVIEWS CANCER (2012)
Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis
Sue Ellen Verbrugge et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Pathogenesis of Myeloma
Kenneth C. Anderson et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1
Yi-Kun Zhang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
Antonio Palumbo et al.
BLOOD (2011)
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Yuan Xiao Zhu et al.
BLOOD (2011)
Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma
Sally A. Hunsucker et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival
Kevin D. Boyd et al.
CLINICAL CANCER RESEARCH (2011)
Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
D. Chen et al.
CURRENT CANCER DRUG TARGETS (2011)
The controversial role of ABC transporters in clinical oncology
Akina Tamaki et al.
ESSAYS IN BIOCHEMISTRY: ABC TRANSPORTERS (2011)
The Clinical Impact and Molecular Biology of del(17p) in Multiple Myeloma Treated with Conventional or Thalidomide-Based Therapy
Kevin D. Boyd et al.
GENES CHROMOSOMES & CANCER (2011)
Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells
Mu Hao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
Targeting HSP 90 Induces Apoptosis and Inhibits Critical Survival and Proliferation Pathways in Multiple Myeloma
Tiffany Khong et al.
MOLECULAR CANCER THERAPEUTICS (2011)
The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells
K. A. Monaghan et al.
LEUKEMIA (2011)
Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation
Xudong Wang et al.
LEUKEMIA & LYMPHOMA (2011)
Treatment of multiple myeloma
S. Vincent Rajkumar
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
MicroRNAs: New Players in Multiple Myeloma
Flavia Pichiorri et al.
Frontiers in Genetics (2011)
MicroRNA Profiles of Drug-Resistant Myeloma Cell Lines
Reinhold Munker et al.
ACTA HAEMATOLOGICA (2010)
Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy
Pavel Nemec et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance
Fiona M. Ross et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma
Laurence Lode et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
Herve Avet-Loiseau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies
M. A. Dimopoulos et al.
LEUKEMIA (2010)
Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome
Ba Thanh-Truc Ngo et al.
LEUKEMIA & LYMPHOMA (2010)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
INCB16562, a JAK1/2 Selective Inhibitor, Is Efficacious against Multiple Myeloma Cells and Reverses the Protective Effects of Cytokine and Stromal Cell Support
Jun Li et al.
NEOPLASIA (2010)
Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis
Patricia Balsas et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
Donna Reece et al.
BLOOD (2009)
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
Paul Richardson et al.
BLOOD (2009)
A monoclonal gammopathy precedes multiple myeloma in most patients
Brendan M. Weiss et al.
BLOOD (2009)
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Ola Landgren et al.
BLOOD (2009)
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma
Aldo M. Roccaro et al.
BLOOD (2009)
The prognostic significance of 8p21 deletion in multiple myeloma
T. Sutlu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib
Manuela Milani et al.
CANCER RESEARCH (2009)
Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
Ashraf Badros et al.
CLINICAL CANCER RESEARCH (2009)
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells
Jose L. R. Brito et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Martha Q. Lacy et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Mechanism of action of lenalidomide in hematological malignancies
Venumadhav Kotla et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo
Renate Burger et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma
Jean-Luc Harousseau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Environment-mediated drug resistance: a major contributor to minimal residual disease
Mark B. Meads et al.
NATURE REVIEWS CANCER (2009)
Treatment of Multiple Myeloma: A Comprehensive Review
Robert A. Kyle et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Molecular basis of bortezomib resistance:: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein
Ruud Oerlemans et al.
BLOOD (2008)
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
William Matsui et al.
CANCER RESEARCH (2008)
Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment
Alissa Huston et al.
CLINICAL CANCER RESEARCH (2008)
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
Eric D. Hsi et al.
CLINICAL CANCER RESEARCH (2008)
Clinical and biological significance of RAS mutations in multiple myeloma
W. J. Chng et al.
LEUKEMIA (2008)
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis
Flavia Pichiorri et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma
Peter M. Voorhees et al.
CLINICAL CANCER RESEARCH (2007)
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna
Deborah J. Kuhn et al.
BLOOD (2007)
Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant
Muzaffar H. Qazilbash et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Interleukin-6-dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer
Dennis Loeffler et al.
BLOOD (2007)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma
Craig D. Peacock et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90α and β in multiple myeloma cells, which critically contribute to tumor-cell survival
Manik Chatterjee et al.
BLOOD (2007)
Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion
V. Sagaster et al.
LEUKEMIA (2007)
ABCG2 expression, function, and promoter methylation in human multiple myeloma
Joel G. Turner et al.
BLOOD (2006)
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng et al.
BLOOD (2006)
Antimyeloma activity of heat shock protein-90 inhibition
CS Mitsiades et al.
BLOOD (2006)
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and-17p13 in myeloma patients treated with high-dose therapy
MA Gertz et al.
BLOOD (2005)
Lenalidomide and thalidomide: Mechanisms of action - Similarities and differences
KC Anderson
SEMINARS IN HEMATOLOGY (2005)
Molecular pathogenesis and a consequent classification of multiple myeloma
PL Bergsagel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival
S Wuillème-Toumi et al.
LEUKEMIA (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Targeting apoptosis pathways in cancer therapy
IM Ghobrial et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells
F Jundt et al.
BLOOD (2004)
Illegitimate WNT signaling promotes proliferation of multiple myeloma cells
PWB Derksen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Characterization of clonogenic multiple myeloma cells
W Matsui et al.
BLOOD (2004)
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma
EM Hurt et al.
CANCER CELL (2004)
The recurrent translocation t(14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB:: a molecular and genetic analysis of the chromosomal breakpoint
GR Boersma-Vreugdenhil et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells
S Lentzsch et al.
LEUKEMIA (2004)
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis
S Le Gouill et al.
BLOOD (2004)
Overcoming drug resistance in multiple myeloma: The emergence of therapeutic approaches to induce apoptosis
HH Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
New insights into the pathophysiology of multiple myeloma
S Seidl et al.
LANCET ONCOLOGY (2003)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells
M Jourdan et al.
ONCOGENE (2003)
Review of 1027 patients with newly diagnosed multiple myeloma
RA Kyle et al.
MAYO CLINIC PROCEEDINGS (2003)
Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells -: Regulation during interleukin-6 (IL-6)-induced growth and survival
H Spets et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2002)
NF-κB as a therapeutic target in multiple myeloma
T Hideshima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Myeloid cell factor-1 is a critical survival factor for multiple myeloma
B Zhang et al.
BLOOD (2002)
Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation
H Avet-Loiseau et al.
BLOOD (2002)
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
CS Mitsiades et al.
BLOOD (2001)
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration
K Podar et al.
BLOOD (2001)
Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity
JA Keifer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations
I Hanamura et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2001)
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma
M Chesi et al.
BLOOD (2001)
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
T Hideshima et al.
BLOOD (2000)
分享论文
